Characterization of three new serous epithelial ovarian cancer cell lines
- Equal contributors
1 Centre de recherche du Centre hospitalier de l'Université de Montréal (CHUM)/Institut du cancer de Montréal, Montreal, Canada
2 The Research Institute of McGill University Health Centre, Montreal, Canada
3 Leukemia Cell Bank of Quebec and Division of Hematology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada
4 Department of Medicine, Université de Montréal, Montreal, Quebec, Canada
5 Department of Human Genetics, McGill University, Montreal, Canada
6 Department of Medicine, McGill University, Montreal, Canada
7 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Université de Montréal, Montreal, Canada
Citation and License
BMC Cancer 2008, 8:152 doi:10.1186/1471-2407-8-152Published: 28 May 2008
Cell lines constitute a powerful model to study cancer, and here we describe three new epithelial ovarian cancer (EOC) cell lines derived from poorly differentiated serous solid tumors (TOV-1946, and TOV-2223G), as well as the matched ascites for one case (OV-1946).
In addition to growth parameters, the cell lines were characterized for anchorage independent growth, migration and invasion potential, ability to form spheroids and xenografts in SCID mice.
While all cell lines were capable of anchorage independent growth, only the TOV-1946 and OV-1946 cell lines were able to form spheroid and produce tumors. Profiling of keratins, p53 and Her2 protein expression was assessed by immunohistochemistry and western blot analyses. Somatic TP53 mutations were found in all cell lines, with TOV-1946 and OV-1946 harboring the same mutation, and none harbored the commonly observed somatic mutations in BRAF, KRAS or germline BRCA1/2 mutations found to recur in the French Canadian population. Conventional cytogenetics and spectral karyotype (SKY) analyses revealed complex karyotypes often observed in ovarian disease.
This is the first report of the establishment of matched EOC cell lines derived from both solid tumor and ascites of the same patient.